Trading halted — News pending (T1)
Halted Aug 21, 2026, 7:50 PM ET ET. No resumption time set. Price and volume are frozen at the last trade until the halt lifts.
Skye Bioscience, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.8M
- Price
- $0.28
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.14%
- Volume
- 974.6K
About
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Quick stats
Shares outstanding35.1M
Computed float33.1M
Float / shares94.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001516551
Websitehttps://skyebioscience.com
AI Summary
AI-generated1/10
criticalbullishm and a
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Bioscience announced a definitive agreement to acquire Redx Pharma, creating a combined company named Fibrx Therapeutics focused on fibrosis and led by Redx’s management team.
The transaction is supported by approximately $125 million in aggregate financings from a syndicate of investors including Abingworth and Redmile, expected to fund operations into 2029 and through key clinical milestones for lead asset RXC008.
Skye shareholders will retain approximately 5.38% ownership in the combined company, receiving CVRs for the legacy nimacimab asset, while the new pipeline features RXC008, a pan-ROCK inhibitor with FDA Fast Track designation and Phase 2 data expected in H2 2028.
Red flags
- Pre-Transaction Skye equity holders diluted to approximately 5.38% ownership
- Complete change of control to Redx management team and board
- Skye's lead program nimacimab was discontinued prior to this transaction